VIB’s antiviral treatment developer has closed its series A round following a $22.6m extension backed by the research institute, V-Bio Ventures and Vives Inter-University Fund.
ExeVir Bio, a Belgium-based antibody therapy spinout of VIB, has closed its series A round at $50m with a $22.6m extension featuring VIB and its V-Bio Ventures affiliate as well as Université catholique de Louvain’s Vives Inter-University Fund.
Venture capital firm Fund+ led the extension, which also featured UCB Ventures, the corporate venturing subsidiary of pharmaceutical firm UCB, as well as SFPI-FPIM, SRIW, Noshaq, SambrInvest and unnamed Belgian family offices.
ExeVir Bio is developing antibody-based therapies to treat…
